Medical
UK
Europe

NovoCure

$50.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.14 (0.28%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NovoCure and other stocks, options, ETFs, and crypto commission-free!

About

NovoCure Limited Ordinary Shares, also called NovoCure, is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Employees
598
Headquarters
St. Helier, Jersey
Founded
2000
Market Cap
4.65B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
829.59K
High Today
$51.44
Low Today
$49.53
Open Price
$49.53
Volume
243.76K
52 Week High
$56.67
52 Week Low
$19.55

Collections

Medical
UK
Europe
Health
Cancer Prevention
Technology
2015 IPO

News

Markets Insider20h

Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

NovoCure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2019, March 29 through April 3, in Atlanta.

39
Seeking Alpha20h

Novocure’s Chief Science Officer retires

Novocure (NASDAQ:NVCR) Chief Science Officer and Head of R&D, Dr. Eilon Kirson will retire effective May 1, to spend more time with his family.

10
Markets Insider21h

Novocure’s Chief Science Officer Retires after 17 Years of Service

NovoCure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with his family.

2

Earnings

-$0.24
-$0.20
-$0.15
-$0.11
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.